Trending Topics

Relapsing Polychondritis Foundation Announces a Powerhouse Healthcare Coalition

Posted on

The Relapsing Polychondritis (RP) Foundation has announced a generous gift to establish the Penn Relapsing Polychondritis Fund, which will support a unique partnership between the University of Pennsylvania RP Program and the National Institutes of Health (NIH) sponsored Vasculitis Clinical Research Consortium (VCRC).

With support from Race for RP, Nancy Linn and Neil Langberg, the Penn Relapsing Polychondritis Fund will expand these exceptional programs that will improve care for patients with RP. RP is an understudied, underdiagnosed, and undertreated systemic inflammatory disease that causes the body to attack its own cartilage and can prove fatal if left untreated.

“The absence of any clinical trials or other high-quality clinical research in relapsing polychondritis has greatly hampered advancing therapies and outcomes for patients with this rare disease,” says Dr. Peter A. Merkel, MD, MPH, Chief, Division of Rheumatology at University of Pennsylvania and principal investigator of the VCRC.

“As a patient, I am extremely pleased the Foundation has implemented its plan to support research to advance a cure for relapsing polychondritis,” said Nancy Linn, Chair of the Relapsing Polychondritis Foundation.  She added, “It is especially gratifying to be working with the internationally-recognized center of excellence at the University of Pennsylvania and the world-renowned leaders in the conduct of clinical and translational research.”

“The Penn RP Program represents the RP Foundation’s unwavering commitment to powerful research initiatives that improve patient care and relentlessly advance the path to a cure,” said David Bammert, President of the Relapsing Polychondritis Foundation.  “It also provides our philanthropic partners with the unprecedented opportunity to support substantive RP research programs as well as the Foundation’s awareness and educational initiatives.”

The Penn RP Program will allow researchers to pursue important projects, including the development of a world-class referral center to examine the impact of the microbiome on RP disease activity.  Eligible patients will be enrolled in a longitudinal study using the existing infrastructure of the VCRC, which is comprised of an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research, with participating centers around the United States and Canada.

At the University of Pennsylvania, patients with RP will have the opportunity to be evaluated by multiple subspecialties in a coordinator patient-centered manner.  Along with Dr. Merkel, patient evaluations will be led by Dr. Shubhasree Banerjee, a faculty member in the Penn Division of Rheumatology who received prior advanced training in the evaluation and management of RP.

Read the full press release here

Source: Relapsing Polychondritis Foundation